Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review.

ABSTRACT:

Background

In patients with hormone receptor-positive breast cancer, differentiating between patients with a low and a high risk of recurrence is an ongoing challenge. In current practice, prognostic clinical parameters are used for risk prediction. DNA methylation markers have been proven to be of additional prognostic value in several cancer types. Numerous prognostic DNA methylation markers for breast cancer have been published in the literature. However, to date, none of these markers are used in clinical practice.

Methods

We conducted a systematic review of PubMed and EMBASE to assess the number and level of evidence of published DNA methylation markers for hormone receptor-positive breast cancer. To obtain an overview of the reporting quality of the included studies, a

SUBMITTER: de Ruijter TC 

PROVIDER: S-EPMC6993426 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature